Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst

The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc ‘s (NYSE: HIMS ) peptide optionality narrative, BofA Securities said. Analyst Allen Lutz maintained a Neutral rating while raising the price target to $36 from $25. The FDA released briefing materials this week ahead of Pharmacy Compounding Advisory Committee (PCAC) meetings reviewing the seven peptides, Lutz said. Check out other analyst stock ratings. He added that: The PCAC meeting is scheduled for July 23 to 24. These seven peptides were planned for discussions. The FDA’s recommendation of these peptides not being included on the 503A Bulk List appears to be preliminary. The FDA will not issue a final determination until it receives inputs from the advisory committee process. The FDA’s key concerns include limited clinical evidence, unresolved safety/quality qu...